Visit TheBody.com for Patient Education
You are not currently logged in.
Login
or
Register
Sign up for free e-mail/fax newsletters!
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy
Antiretroviral Therapy
Acute Infection
Antiretrovirals
Assays (Diagnostic & Monitoring)
Guidelines
Initial Therapy
Pediatrics
Resistance
Salvage Therapy
Second/Third-Line Treatment
Structured Treatment Interruptions
Women & Pregnancy
More ...
Complications of HIV/HAART
Complications of HIV/HAART
Overview
Cardiovascular
Lipoatrophy
Gastrointestinal
Hepatitis
HPV & Cervical/Anal Cancer
Liver Complications
Malignancies
Mental Health
Metabolic
Neurocognitive
Renal Complications
Women-Specific
More ...
Research & Development
Research & Development
Overview
Antiretrovirals in Development
Conference Reports
HIV Genetics
HIV Immunology
More ...
Clinical Trials
Clinical Trials
Overview & News
U.S. Databases
U.S. Nationwide Studies
U.S. State-by-State Trial Listings
Databases Outside U.S.
Specific Trials Outside U.S.
More ...
Quality of Life & Patient Care
Quality of Life & Patient Care
Complementary Medicine
Mental Health
Primary Care
Cryptococcosis
Overview
|
Treatment
Preferred Therapy and Duration
Recommendation from the U.S. Centers for Disease Control and Prevention
Acute infection (induction therapy)
Amphotericin B deoxycholate 0.7 mg/kg body weight IV QD and/or flucytosine 25 mg/kg PO QID for 2 weeks (
AI
); or
Liposomal Amphotericin B 4 mg/kg IV QD and/or flucytosine 25 mg/kg PO QID for 2 weeks (
AI
)
For full recommendations, click
here
Overview
Cryptococcosis and HIV
(October 2002)
Another chapter from the comprehensive, online textbook on HIV disease from the University of California-San Francisco and San Francisco General Hospital.
From HIV InSite
Treatment
Cryptococcosis
(December 17, 2004)
A chapter from "Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents" guidelines.
To read PDF,
click here
In
Morbidity and Mortality Weekly Report
, from
U.S. Centers for Disease Control and Prevention
Opportunistic Infection News: PCP Developing Resistance to Some Antibiotics
(Autumn 2000)
In
Bulletin of Experimental Treatments for AIDS
, from
San Francisco AIDS Foundation
Discontinuing Primary and Secondary PCP Prophylaxis in Patients Who Have Increased CD4 Counts in Response to Antiretroviral Therapy: Preliminary Results -- ACTG 888
(January 31, 2000)
In
The 7th Conference on Retroviruses and Opportunistic Infections
, from
The Body PRO